Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.48 Analyst target: $13.67 Upside: 61.20%
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.